September 22, 2008
Webcast Alert: ATL/TV1102 Phase II Results Presented at the World Congress on Treatment and Research in Multiple Sclerosis Conference Call
CARLSBAD, Calif., Sept. 22 /PRNewswire-FirstCall/ -- Antisense Therapeutics Ltd. and Isis Pharmaceuticals, Inc. announces the following webcast:
What: ATL/TV1102 Phase II results presented at the World Congress on Treatment and Research in Multiple Sclerosis When: Monday, September 22, 2008, at 5:00 p.m. ET / 2:00 p.m. PT Tuesday, September 23, 2008, at 7:00 a.m. EST (Melbourne time) Where: http://www.antisense.com.au/ and http://www.isispharm.com/ How: Live on the Internet. Simply log onto either of the websites listed above. Contacts: Simon Watkin Investor Relations Antisense Therapeutics Ltd. +61 (0) 413-153272 Kristina Lemonidis Associate Director, Corporate Development Isis Pharmaceuticals, Inc. (760) 603-2490 Amy Blackley, Ph.D. Manager, Corporate Communications Isis Pharmaceuticals, Inc. (760) 603-2772
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.antisense.com.au/ and http://www.isispharm.com/.About Antisense Therapeutics Limited
Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialize antisense pharmaceuticals for large unmet markets. ANP has two drugs in development and two drugs in pre-clinical research. ATL/TV1102 (injection) has completed a Phase IIa trial as a potential treatment of multiple sclerosis. ATL1103 is a second-generation antisense drug designed to lower blood IGF-I levels and is entering pre-clinical development as a potential treatment for acromegaly and vision disorders. ATL/TV1102 (inhaled) is at the pre-clinical research stage as a potential treatment for asthma. ATL1101 is a second-generation antisense drug at the pre-clinical research stage being investigated as a potential treatment for prostate cancer. ATL/TV1102 has been licensed to Teva Pharmaceutical Industries Ltd.
About Isis Pharmaceuticals, Inc.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com/.
Antisense Therapeutics Ltd.; Isis Pharmaceuticals, Inc.
CONTACT: Simon Watkin, Investor Relations of Antisense Therapeutics Ltd.,+61 (0) 413-153272; or Kristina Lemonidis, Associate Director, CorporateDevelopment, +1-760-603-2490, or Amy Blackley, Ph.D., Manager, CorporateCommunications, +1-760-603-2772, both of Isis Pharmaceuticals, Inc.
Web site: http://www.antisense.com.au/http://www.isispharm.com/